Following the recent reclassification of repeated low-level red-light (RLRL) therapy in China, Eyerising International is hosting an online CPD event where attendees can engage in a Q&A with the device’s inventor and hear from a Chinese professor on a real-world study of over 2,000 patients in his country.
Professor Junwen Zeng, chairman of the Refraction and Low Vision Department at Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, will feature in the 26 March 2025 webinar alongside Professor Mingguang He, founder of RLRL and Chair Professor of Experimental Ophthalmology at Hong Kong Polytechnic University.
Entitled ‘RLRL in China: Real-world Experiences by Eyerising International’, the virtual event is CPD-accredited through Optometry Australia for 1.25 hours, while New Zealand CPD is pending.
Prof Zeng will be sharing his real-world study of more than 2,000 patients using RLRL in China, as well his insights into current use of RLRL following the reclassification.
Prof He will also be joining the Q&A session of this webinar to discuss numerous ongoing studies of RLRL and real-world use in China and beyond.
The webinar is hosted by Eyerising International, the manufacturer of the Eyerising Myopia Management Device which has been approved by the Therapeutic Goods Administration in Australia since 2023.
Numerous studies have demonstrated children who undergo RLRL for three minutes twice a day, five days a week, experience a significant reduction in myopia progression over a 12-month period, with a 69.4% efficacy in controlling axial length elongation and a 76.6% efficacy in managing spherical equivalence progression.
Questions over the safety of RLRL have been raised in the academic world following news of the China reclassification, but unlike other RLRL devices in China, Eyerising International states its device is the only device to have received Class IIa/Class B regulatory approvals internationally, “based on strong evidence of its efficacy and safety”.
It has also implemented safety precautions and stringent monitoring in all international use of the Eyerising device due to it being a newer myopia control treatment.
The webinar is outlined to:
- Examine real-world studies showcasing patient outcomes.
- Clarify rumours about RLRL, including following news of the China reclassification.
- Discuss clinical evidence underpinning RLRL as a myopia control option.
- Open Q&A with both professors (final 20 minutes).
Eyerising International describes this as “a must-attend event for optometrists, ophthalmologists, and eye care professionals looking to gain confidence in discussing RLRL therapy with their patients”.
Details
Date: March 26th 2025
Time: 6:30 pm AEDT (Melbourne, Sydney, Canberra)
Location: Microsoft Teams Webinar, register here.
More reading
Eyerising International responds to China myopia red light regulatory changes
Tokyo Medical and Dental University introduces Eyerising red light therapy for myopic patients
Eyerising International refutes ‘inaccurate claims’ in University of Houston red light myopia study
